81 related articles for article (PubMed ID: 20854749)
1. Biomarkers for the early stages of clinical development in Alzheimer's disease.
Bordet R; Dartigues JF; Dubois B; Goehrs JM; Vernoux L; Semah F; Pasquier F; Bidaut-Mazel C;
Therapie; 2010; 65(4):285-90, 277-283. PubMed ID: 20854749
[TBL] [Abstract][Full Text] [Related]
2. Optimizing phase II of drug development for disease-modifying compounds.
Cummings JL
Alzheimers Dement; 2008 Jan; 4(1 Suppl 1):S15-20. PubMed ID: 18631992
[TBL] [Abstract][Full Text] [Related]
3. Prevention trials in Alzheimer's disease: an EU-US task force report.
Vellas B; Aisen PS; Sampaio C; Carrillo M; Scheltens P; Scherrer B; Frisoni GB; Weiner M; Schneider L; Gauthier S; Gispen-de Wied CC; Hendrix S; Feldman H; Cedarbaum J; Petersen R; Siemers E; Andrieu S; Prvulovic D; Touchon J; Hampel H
Prog Neurobiol; 2011 Dec; 95(4):594-600. PubMed ID: 21925234
[TBL] [Abstract][Full Text] [Related]
4. Complex disease-associated pharmacogenetics: drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease).
Roses AD; Saunders AM; Huang Y; Strum J; Weisgraber KH; Mahley RW
Pharmacogenomics J; 2007 Feb; 7(1):10-28. PubMed ID: 16770341
[TBL] [Abstract][Full Text] [Related]
5. Relevance of the evaluation criteria used in clinical trials for Alzheimer's disease.
Truffinet P; Bordet R; Ménard J
Therapie; 2009; 64(3):139-8. PubMed ID: 19671425
[TBL] [Abstract][Full Text] [Related]
6. Can we do better in developing new drugs for Alzheimer's disease?
Gauthier S; Scheltens P
Alzheimers Dement; 2009 Nov; 5(6):489-91. PubMed ID: 19896588
[TBL] [Abstract][Full Text] [Related]
7. Measuring cognitive change in Alzheimer's disease clinical drug trials.
Harrison JE
J Nutr Health Aging; 2007; 11(4):327-9. PubMed ID: 17653492
[TBL] [Abstract][Full Text] [Related]
8. Six and 18-month changes in mild to moderate Alzheimer's patients treated with acetylcholinesterase inhibitors: what can we learn for clinical outcomes of therapeutic trials?
Cortes F; Portet F; Touchon J; Vellas B
J Nutr Health Aging; 2007; 11(4):330-7. PubMed ID: 17653493
[TBL] [Abstract][Full Text] [Related]
9. Alternative strategies in drug development: clinical pharmacological aspects.
Kuhlmann J
Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
[TBL] [Abstract][Full Text] [Related]
10. Biomarkers in preclinical Alzheimer's disease.
Chong MS; Lim WS; Sahadevan S
Curr Opin Investig Drugs; 2006 Jul; 7(7):600-7. PubMed ID: 16869111
[TBL] [Abstract][Full Text] [Related]
11. Citicoline. Ferrer Internacional.
Alexandrov AV
Curr Opin Investig Drugs; 2001 Dec; 2(12):1757-62. PubMed ID: 11892942
[TBL] [Abstract][Full Text] [Related]
12. [Medical treatment of Alzheimer's disease].
López-Pousa S; Serra-Mestres J
Rev Neurol; 1998 Jun; 26(154):1054-60. PubMed ID: 9658492
[TBL] [Abstract][Full Text] [Related]
13. Improving Alzheimer's disease phase II clinical trials.
Greenberg BD; Carrillo MC; Ryan JM; Gold M; Gallagher K; Grundman M; Berman RM; Ashwood T; Siemers ER
Alzheimers Dement; 2013 Jan; 9(1):39-49. PubMed ID: 23164548
[TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal fluid biomarkers for Alzheimer's disease.
Blennow K; Zetterberg H
J Alzheimers Dis; 2009; 18(2):413-7. PubMed ID: 19661632
[TBL] [Abstract][Full Text] [Related]
15. Assessing health economic outcome in Alzheimer's disease clinical trials.
Jonsson L
J Nutr Health Aging; 2007; 11(4):353-5. PubMed ID: 17653498
[TBL] [Abstract][Full Text] [Related]
16. Recommendations for best practices in the treatment of Alzheimer's disease in managed care.
Fillit HM; Doody RS; Binaso K; Crooks GM; Ferris SH; Farlow MR; Leifer B; Mills C; Minkoff N; Orland B; Reichman WE; Salloway S
Am J Geriatr Pharmacother; 2006; 4 Suppl A():S9-S24; quiz S25-S28. PubMed ID: 17157793
[TBL] [Abstract][Full Text] [Related]
17. ApoE genotyping as a progression-rate biomarker in phase II disease-modification trials for Alzheimer's disease.
Stone DJ; Molony C; Suver C; Schadt EE; Potter WZ
Pharmacogenomics J; 2010 Jun; 10(3):161-4. PubMed ID: 19997085
[No Abstract] [Full Text] [Related]
18. A phased approach to clinical testing: criteria for progressing from Phase I to Phase II to Phase III studies.
André FE; Foulkes MA
Dev Biol Stand; 1998; 95():57-60. PubMed ID: 9855414
[TBL] [Abstract][Full Text] [Related]
19. Early clinical trials in Alzheimer's disease: selection and evaluation of drug candidates.
Reines SA
Prog Clin Biol Res; 1989; 317():1283-90. PubMed ID: 2690095
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers in clinical trials for neurodegenerative diseases: regulatory perspectives and requirements.
Broich K; Weiergräber M; Hampel H
Prog Neurobiol; 2011 Dec; 95(4):498-500. PubMed ID: 21945642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
